SV2011003904A - Composiciones y metodos de uso para variantes de trombomodulina - Google Patents
Composiciones y metodos de uso para variantes de trombomodulinaInfo
- Publication number
- SV2011003904A SV2011003904A SV2011003904A SV2011003904A SV2011003904A SV 2011003904 A SV2011003904 A SV 2011003904A SV 2011003904 A SV2011003904 A SV 2011003904A SV 2011003904 A SV2011003904 A SV 2011003904A SV 2011003904 A SV2011003904 A SV 2011003904A
- Authority
- SV
- El Salvador
- Prior art keywords
- compositions
- methods
- variants
- thrombomodulin variants
- patient
- Prior art date
Links
- 102000012607 Thrombomodulin Human genes 0.000 title abstract 3
- 108010079274 Thrombomodulin Proteins 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title 1
- 108090000190 Thrombin Proteins 0.000 abstract 2
- 229960004072 thrombin Drugs 0.000 abstract 2
- 230000009692 acute damage Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/366—Thrombomodulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/7455—Thrombomodulin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Hematology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
UN MÉTODO PARA PREVENIR Y/O TRATAR UN PACIENTE CON UNA LESIÓN REAL AGUDA CAUSADA POR UNA VARIEDAD DE CONDICIONES. EL MÉTODO COMPRENDE LA ADMINISTRACIÓN AL PACIENTE VARIANTES DE TROMBOMODULINA SOLUBLE QUE NO SE UNE A TROMBINA, JUNTO CON EL ESTÁNDAR DE CUIDADO, VARIANTES DE TROMBOMODULINA SOLUBLE QUE NO SE UNEN A TROMBINA PREVENDRÁN O REDUCIRÁN LA LESIÓN REAL AGUDA Y POSTERIOR MORBILIDAD Y MORTALIDAD
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11380108P | 2008-11-12 | 2008-11-12 |
Publications (1)
Publication Number | Publication Date |
---|---|
SV2011003904A true SV2011003904A (es) | 2011-07-06 |
Family
ID=42111790
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SV2011003904A SV2011003904A (es) | 2008-11-12 | 2011-05-12 | Composiciones y metodos de uso para variantes de trombomodulina |
Country Status (21)
Country | Link |
---|---|
US (1) | US20110207670A1 (es) |
EP (1) | EP2355839A2 (es) |
JP (1) | JP2012508742A (es) |
KR (1) | KR20110083665A (es) |
CN (1) | CN102216326A (es) |
AU (1) | AU2009314413A1 (es) |
BR (1) | BRPI0922033A2 (es) |
CA (1) | CA2743141A1 (es) |
CL (1) | CL2011001065A1 (es) |
CO (1) | CO6362021A2 (es) |
CR (1) | CR20110239A (es) |
DO (1) | DOP2011000133A (es) |
EA (1) | EA201170679A1 (es) |
EC (1) | ECSP11011049A (es) |
IL (1) | IL212209A0 (es) |
MA (1) | MA32775B1 (es) |
MX (1) | MX2011005005A (es) |
SV (1) | SV2011003904A (es) |
TN (1) | TN2011000206A1 (es) |
WO (1) | WO2010056472A2 (es) |
ZA (1) | ZA201103179B (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014020183A1 (de) * | 2012-08-03 | 2014-02-06 | Ici Immunochemical Intelligence Gmbh | In-vitro-assay zur diagnose von störungen der hämostase |
WO2021126822A1 (en) * | 2019-12-20 | 2021-06-24 | Blue Blood Biotech Corp. | Thrombomodulin functional domains for use in promoting osteoblast functions and bone healing |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2065409C (en) * | 1990-06-27 | 2002-05-14 | Mochida Pharmaceutical Co., Ltd. | Anticoagulant polypeptides |
WO1995016460A1 (fr) * | 1993-12-17 | 1995-06-22 | Mochida Pharmaceutical Co., Ltd. | Dispositif a semi-conducteur |
US5916874A (en) * | 1994-04-20 | 1999-06-29 | Asahi Kasei Kogyo Kabushiki Kaisha | Method for treating liver injury |
US5639625A (en) * | 1994-09-26 | 1997-06-17 | Oklahoma Medical Research Foundation | Method for detecting antibodies to thrombomodulin in patients |
WO2004050844A2 (en) * | 2002-12-02 | 2004-06-17 | Biovec Llc | Ex vivo and in vivo expression of the thrombomodulin gene for the treatment of cardiovascular and peripheral vascular diseases |
WO2004076635A2 (en) * | 2003-02-25 | 2004-09-10 | Biovec B.V. | Therapeutic applications of thrombomodulin gene via viral and non-viral vectors |
DK1948216T3 (da) * | 2005-10-13 | 2011-06-06 | Lilly Co Eli | Behandling af akut nyresvigt med opløselig thrombomodulin |
RU2433829C2 (ru) * | 2006-10-06 | 2011-11-20 | Асахи Касеи Фарма Корпорейшн | Средство для лечения и/или улучшения состояния при диссеминированном внутрисосудистом свертывании |
US8076298B2 (en) * | 2006-12-12 | 2011-12-13 | Eli Lilly And Company | Treating acute renal failure with soluble thrombomodulin variants |
-
2009
- 2009-10-21 JP JP2011536368A patent/JP2012508742A/ja not_active Withdrawn
- 2009-10-21 WO PCT/US2009/061407 patent/WO2010056472A2/en active Application Filing
- 2009-10-21 CN CN2009801451443A patent/CN102216326A/zh active Pending
- 2009-10-21 BR BRPI0922033A patent/BRPI0922033A2/pt not_active Application Discontinuation
- 2009-10-21 US US13/126,474 patent/US20110207670A1/en not_active Abandoned
- 2009-10-21 EA EA201170679A patent/EA201170679A1/ru unknown
- 2009-10-21 KR KR1020117010724A patent/KR20110083665A/ko not_active Ceased
- 2009-10-21 AU AU2009314413A patent/AU2009314413A1/en not_active Abandoned
- 2009-10-21 MX MX2011005005A patent/MX2011005005A/es not_active Application Discontinuation
- 2009-10-21 EP EP09740604A patent/EP2355839A2/en not_active Withdrawn
- 2009-10-21 CA CA2743141A patent/CA2743141A1/en not_active Abandoned
-
2011
- 2011-04-07 IL IL212209A patent/IL212209A0/en unknown
- 2011-04-25 TN TN2011000206A patent/TN2011000206A1/fr unknown
- 2011-04-29 ZA ZA2011/03179A patent/ZA201103179B/en unknown
- 2011-05-06 CR CR20110239A patent/CR20110239A/es not_active Application Discontinuation
- 2011-05-09 MA MA33821A patent/MA32775B1/fr unknown
- 2011-05-11 CL CL2011001065A patent/CL2011001065A1/es unknown
- 2011-05-11 DO DO2011000133A patent/DOP2011000133A/es unknown
- 2011-05-12 SV SV2011003904A patent/SV2011003904A/es unknown
- 2011-05-12 CO CO11058574A patent/CO6362021A2/es not_active Application Discontinuation
- 2011-05-12 EC EC2011011049A patent/ECSP11011049A/es unknown
Also Published As
Publication number | Publication date |
---|---|
MA32775B1 (fr) | 2011-11-01 |
WO2010056472A2 (en) | 2010-05-20 |
MX2011005005A (es) | 2011-05-25 |
EA201170679A1 (ru) | 2012-04-30 |
AU2009314413A1 (en) | 2010-05-20 |
CN102216326A (zh) | 2011-10-12 |
JP2012508742A (ja) | 2012-04-12 |
IL212209A0 (en) | 2011-06-30 |
CL2011001065A1 (es) | 2011-10-07 |
ZA201103179B (en) | 2012-10-31 |
ECSP11011049A (es) | 2011-06-30 |
BRPI0922033A2 (pt) | 2015-12-15 |
DOP2011000133A (es) | 2011-06-30 |
KR20110083665A (ko) | 2011-07-20 |
CO6362021A2 (es) | 2012-01-20 |
EP2355839A2 (en) | 2011-08-17 |
WO2010056472A3 (en) | 2010-08-19 |
CR20110239A (es) | 2011-06-09 |
US20110207670A1 (en) | 2011-08-25 |
CA2743141A1 (en) | 2010-05-20 |
TN2011000206A1 (en) | 2012-12-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2019003798A1 (es) | Métodos para tratar la enfermedad de huntington. | |
CY1123470T1 (el) | Αναστολεις ιβατ για την αγωγη ηπατοπαθειων | |
CL2016002262A1 (es) | Composiciones y métodos para modular la expresión de ttr y vhb | |
CL2019000107A1 (es) | Composiciones de arni contra el componente c5 del complemento y métodos para su uso.(divisional solicitud 201702014) | |
CO2018003168A2 (es) | Moduladores de la expresión de kras | |
BR112013001619A2 (pt) | método, e, composição | |
ECSP10010548A (es) | Composiciones y metodos de preparacion y uso de las mismas | |
MX346450B (es) | Composiciones y métodos para el tratamiento de la enfermedad celíaca. | |
UY31816A (es) | Agente para el tratamiento y/o prevención de una enfemedad autoinmune y para la formación de células t reguladoras | |
GT201400136A (es) | Compuestos y métodos de benzaldehído substituído para su uso en incrementar la oxigenación de los tejidos | |
CO7160059A2 (es) | Formulación líquida | |
MX367241B (es) | Uso de anticuerpos contra claudina 18.2 en una terapia de combinación para el tratamiento de cáncer. | |
AR056816A1 (es) | Composicion con ácido docosapentenoico | |
CL2010000188A1 (es) | Metodo para el tratamiento de una infeccion en un sujeto que comprende la administracion de 9-[(2,2-dimetil-propilamino)-metil]-minociclina o de una sal de la misma; composicion farmaceutica que comprende dicho compuesto; y su uso. | |
CL2008003653A1 (es) | Uso de un inhibidor de sglt derivado de glucopiranosilo y un inhibidor de dppiv seleccionado para tratar la diabetes; y composicion farmaceutica. | |
CR11548A (es) | Azolilmetiloxiranos, su uso y agentes que los contienen | |
UY30304A1 (es) | Moduladores de mglur5 i | |
CL2009001298A1 (es) | Compuestos derivados de n-ciclohexil-2-fenoxinicotinamida; composición farmcéutica que los comprende; combinación farmacéutica que los comprende; y su uso para tratar una enfermedad mediada por la pde4. | |
CU24349B1 (es) | Composiciones que comprenden 2,3-dihidroimidazo [1,2-c] quinazolinas sustituidas útiles para el tratamiento del cáncer | |
EA201200484A1 (ru) | Фармацевтическая композиция с действующими веществами - метформином и ситаглиптином или вилдаглиптином | |
AR056500A1 (es) | Metodo para preparar una composicion medica | |
CY1115081T1 (el) | Νεο εκχυλισμα απο γαϊδουραγκαθο, μεθοδος για την παρασκευη και η χρηση του | |
CL2009000803A1 (es) | Uso de una variante de igf-1 pegilada para tratar, prevenir un trastorno neuromuscular; metodo para el tratamiento, prevencion y/o demora de un trastorno neuromuscular; composicion que comprende la variante de igf-1 modificada | |
BR112014024220A2 (pt) | genes que codificam celulase | |
CR20110190A (es) | Agente rodenticida sinérgico |